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Themechanistic target of rapamycin (mTOR) signaling pathway is a crucial cellular signaling hub that, like the
nervous system itself, integrates internal and external cues to elicit critical outputs including growth control,
protein synthesis, gene expression, andmetabolic balance. The importance of mTOR signaling to brain func-
tion is underscored by the myriad disorders in which mTOR pathway dysfunction is implicated, such as
autism, epilepsy, and neurodegenerative disorders. Pharmacological manipulation of mTOR signaling holds
therapeutic promise and has entered clinical trials for several disorders. Here, we review the functions of
mTOR signaling in the normal and pathological brain, highlighting ongoing efforts to translate our under-
standing of cellular physiology into direct medical benefit for neurological disorders.The mechanistic target of rapamycin (mTOR) signaling pathway
acts as a molecular systems integrator to support organismal
and cellular interactions with the environment. The mTOR
pathway regulates homeostasis by directly influencing protein
synthesis, transcription, autophagy, metabolism, and organelle
biogenesis and maintenance. It is not surprising then that
mTOR signaling is implicated in the entire hierarchy of brain func-
tion including the proliferation of neural stem cells, the assembly
and maintenance of circuits, experience-dependent plasticity,
and regulation of complex behaviors like feeding, sleep, and
circadian rhythms. mTOR dysfunction is the root cause of se-
veral monogenetic disorders and is implicated in both neurode-
generative and neuropsychiatric diseases. Pharmacological
manipulation of the mTOR pathway is proving to be a promising
branch of neurotherapeutics. To provide a framework for consid-
ering the potential of these new therapeutic opportunities, in this
review we will illustrate the interrelatedness of neurological dis-
orders through the lens of this multifaceted and ubiquitous mo-
lecular pathway.
The mTOR Signaling Network
The mTOR Complexes
From a scratch of soil culled from the ground of Easter Island
(Rapa Nui in Polynesian), the soil bacteria Streptomyces hygro-
scopicus yielded the antifungal macrolide eponymously dubbed
‘‘rapamycin,’’ leading to the discovery of the mechanistic target
of rapamycin (mTOR; Brown et al., 1994; Sabatini et al., 1994).
mTOR is a large (259 kDa), highly conserved, serine/threonine
kinase that is an atypical member of the phosphoinositide 3-ki-
nase-related kinase family and is ubiquitously expressed in
eukaryotic cell types, including neural cells (Sabatini et al.,
1999)(Figure 1A).
mTOR function is mediated through two large biochemical
complexes defined by their respective protein composition and
have been extensively reviewed elsewhere (Dibble andManning,
2013; Laplante and Sabatini, 2012) (Figure 1B). In brief, common
to both mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2) are mTOR itself, mammalian lethal with sec13 protein8 (mLST8; also known as GbL), and the inhibitory DEP domain
containing mTOR-interacting protein (DEPTOR). Specific to
mTORC1 is the regulator-associated protein of the mammalian
target of rapamycin (Raptor) and proline-rich Akt substrate of
40 kDa (PRAS40) (Kim et al., 2002; Laplante and Sabatini,
2012). Raptor is essential to mTORC1 activity.
The mTORC2 complex includes the rapamycin-insensitive
companion of mTOR (Rictor), mammalian stress-activated MAP
kinase-interacting protein 1 (mSIN1), and proteins observed
with rictor 1 and 2 (PROTOR 1 and 2) (Jacinto et al., 2004,
2006; Pearce et al., 2007; Sarbassov et al., 2004) (Figure 1B). Ric-
tor and mSIN1 are both critical to mTORC2 function.
FKBP12 is a nonobligate mTOR-interacting protein that posi-
tively influences mTOR function and binds rapamycin only when
incorporated into mTORC1 complex (Brown et al., 1994; Chen
et al., 1995; Sabatini et al., 1994; Stan et al., 1994) (Figure 1B).
The fact that rapamycin acts by blocking the interaction of
FKBP12 with mTOR is a possible explanation for the pharmaco-
logical proclivity of rapamycin for mTORC1. Indeed, mTORC2
was originally considered rapamycin-insensitive; however, more
recent studies have suggested that long-term rapamycin expo-
sure also inhibits mTORC2 (Jacinto et al., 2004; Loewith et al.,
2002; Sarbassov et al., 2006). This may be partially explained
by observations that high concentrations of rapamycin directly
interact with mTOR within the FKBP12-rapamycin binding
domain (FRB) (Figure 1A; Yang et al., 2013).
Upstream Signaling
Extracellular activators of the mTOR pathway with relevance
to the brain include brain-derived neurotrophic factor (BDNF),
insulin, insulin-like growth factor 1 (IGF1), vascular endothelial
growth factor (VEGF) and ciliary neurotrophic factor (CNTF),
glutamate, and guidance molecules (Lenz and Avruch, 2005;
Nie et al., 2010; Quevedo et al., 2002; Takei et al., 2004).
mTORC1 is potently activated by a small GTPase called Ras
homolog enriched in brain (Rheb). The activity of Rheb is in
turn suppressed by the tuberous sclerosis complex (TSC),
comprised of the tumor suppressors TSC1 (hamartin) and
TSC2 (tuberin), and the recently defined TBC1D7, which actNeuron 84, October 22, 2014 ª2014 Elsevier Inc. 275
Figure 1. Domain Structure of the mTOR
Kinase and Components of Its Protein
Complexes
(A) Domain organization of the mTOR kinase.
HEAT (huntingtin, elongation factor 3, a subunit of
phosphatase 2A and TOR1) repeats mediate
protein interactions with Raptor, Rictor, and other
proteins; FKBP12-rapamycin binding domain
(FRB) is the site of rapamycin-mediated inhibition
of mTORC1. The PIKK kinase domain contains the
Ser/Thr catalytic activity and is the site of inhibition
of kinase-site inhibitors such as Torin1 and Torin II,
which inhibit both mTORC1 and mTORC2 activity.
FATC, FRAP-ATM-TTRAP domain.
(B) The components of mTORC1 and mTORC2.
mTOR, mechanistic target of rapamycin; Raptor,
scaffolding protein essential to mTORC1 activity
and rapamycin sensitivity; PRAS40, an inhibitor of
mTORC1; DEPTOR, an inhibitor of mTORC1;
mLST8/GbL, function unclear; Rictor, scaffold
protein essential to mTORC2 function; mSIN1,
important for mTORC2 enzymatic activity toward
AKT; Protor, mediates activity toward SGK. Black
outlines indicate proteins that have been thor-
oughly examined in the nervous system. The
dashed line around FKBP12 indicates that it is a
nonobligate component of mTORC1.
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active Rheb-GTP to inactive Rheb-GDP and suppressmTOR (In-
oki et al., 2003; Li et al., 2004). Only TSC2 contains GAP function,
however, both TSC1 and TSC2 are required for functionality of
this heterodimer (Figure 2).
The function of TSC is additionally under regulation by several
kinase cascades. Inhibitory influences include extracellular
signal related kinase (ERK), ribosomal S6 kinase (p90-RSK),
AKT, and Wnt-signaling through glycogen synthase kinase 3b
(GSK-3b), which lead to an increase in mTOR activity through
suppression of TSC2 activity. Independent of TSC2, AKT also
stimulates mTOR activity directly by inhibiting PRAS40 (Oshiro
et al., 2007; Sancak et al., 2007; Vander Haar et al., 2007). Further
upstream, phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN) can inactivate PI3K and thus suppress signaling
to mTOR (Figure 2).
AMP-dependent kinase (AMPK) regulates mTOR signaling via
multiple cellular mechanisms. AMPK is activated by a high AMP/
ATP ratio and thereby functions as a key sensor of relative en-
ergy status in the cell upstream ofmTOR. First, AMPK phosphor-
ylates and activates TSC2 function to suppress mTOR activity
(Figure 2). Second, AMPK directly inhibits mTORC1 by phos-
phorylating Raptor (Gwinn et al., 2008). Thus, low energy states
in which the AMP/ATP ratio is high results in increased AMPK
activity and suppression of mTOR-mediated growth pathways
(Inoki et al., 2012).
An additional role for mTOR in cellular sensing of nutrients has
been established, but not well studied in neural systems (Fig-
ure 2). The mTOR pathway senses amino acids through the
Rag family of GTPases and the TSC1/2 complex to promote
the interaction of mTOR with Rheb (Menon et al., 2014; Zoncu
et al., 2011a). The Rags are maintained inactive by a lyso-
some-bound complex called the ‘‘Ragulator’’ and are activated
by sequential action of two multiprotein complexes collectively
termed GATOR1 and GATOR2, which demonstrate GAP activity276 Neuron 84, October 22, 2014 ª2014 Elsevier Inc.to the Rags (Bar-Peled et al., 2012; Efeyan et al., 2013; Zoncu
et al., 2011b).
Activation of mTORC2 in brain has not been widely studied.
mTORC2 has an important role in cell survival and in the mainte-
nance of the actin cytoskeleton and is implicated in the morpho-
logical regulation of actin-rich dendritic spines (Huang et al., 2013;
Jacinto et al., 2004; Sarbassov et al., 2006; Thomanetz et al.,
2013). In yeast and cancer cells, mTORC2 associates with the
ribosome, which appears to be crucial to mTORC2 activation
(Zinzalla et al., 2011). Because mTORC1 stimulates ribosome
assembly, mTORC1 and mTORC2 are, in certain regards, both
upstream and downstream of one another, making the dissection
of their intertwined signaling properties complicated (Figure 2).
Downstream of mTOR Protein Synthesis
mTOR regulates mRNA translation. The best-characterized sub-
strates of mTORC1 are the p70 ribosomal S6 protein kinases 1
and 2 (S6K1/2) and the eukaryotic initiation factor 4E-binding
proteins (4E-BPs) (Figure 2). S6K1/2 are partially redundant ki-
nases encoded by separate genes. Both have unique and shared
substrates. The ribosomal protein S6 (S6) is phosphorylated by
both kinases (Fenton and Gout, 2011). S6K1 also phosphory-
lates eIF4B and eukaryotic elongation factor 2 kinase (eEF2K),
further stimulating translation initiation and elongation of nascent
peptide chains (Ma and Blenis, 2009).
The majority of regulated eukaryotic mRNAs contain a methyl-
ated guanosine repeat at their 50-untranslated regions referred to
as ‘‘the cap.’’ This structure is regulated by binding of the cap
binding protein, eukaryotic initiation factor 4E (eIF4E). eIF4E is
regulated by binding of 4E-BPs, which inhibit the latter’s associ-
ation with the mRNA cap and suppress translation initiation
(Richter and Sonenberg, 2005). 4E-BPs compete with the scaf-
folding protein eIF4G for eIF4E binding. mTOR phosphoryla-
tion of 4E-BPs results in the release of eIF4E to the mRNA cap
structure and subsequent recruitment of eIF4G and the RNA
helicase eIF4A, among many other factors (Ma and Blenis,
Figure 2. The mTOR Signaling Pathway
The mTOR complexes integrate signals from nutrients, growth factors, cytokines, and various intracellular influences to elicit a variety of crucial cellular re-
sponses. Although there are thousands of mTOR substrates, those that have been best characterized in the regulation of crucial cellular processes such as
protein synthesis and autophagy are depicted. RTKs, receptor tyrosine kinases; TrkB, tyrosine receptor kinase B, the receptor for BDNF (brain-derived neu-
rotrophic factor); mGluRs, metabotropic glutamate receptors; NMDA-R, N-methyl-D-aspartate receptor; PGC-1a, peroxisome proliferator-activated receptor
gamma coactivator 1-alpha. Green halos indicate human disease genes.
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stimulated in direct response to mTORC1 activation.
Transcriptional Targets of mTOR
Although the role of mTORC1 in the control of protein synthesis
has beenwidely studied, there is less known about howmTORC1
signaling affects gene expression. Among the best-studied tran-
scription factors regulated by mTORC1 are the sterol-response
binding proteins (SREBPs), which regulate lipogenesis (Peterson
et al., 2011). The functions of the SREBPs in the brain are not fully
understood; however, they have proposed roles in nutrient
sensing, excitotoxicity, myelination, and neurodegenerative dis-
eases (Barbero-Camps et al., 2013; Lebrun-Julien et al., 2014;
Taghibiglou et al., 2009).
mTOR regulates the cellular response to hypoxia through
regulation of the transcription and translation of the hypoxia
inducible factor 1a (HIF1a) (Hudson et al., 2002). HIF1a is a tran-
scription factor that shifts metabolism from oxidative phos-
phorylation toward glycolysis in response to low oxygen tension.HIF1a-mediated mechanisms are required for angiogenesis
following hypoxia and have been implicated in stroke, neonatal
hypoxic-ischemic injury, and neurodegenerative disease (Sharp
and Bernaudin, 2004).
mTOR pathway activation stimulates the association of the
YY1 transcription factor with the transcriptional coactivator
PGC1a and results in the preferential activation of a mitochon-
drial gene program (Cunningham et al., 2007). A recent study
demonstrated that rapamycin had beneficial effects on a mouse
model of the neurodegenerative mitochondropathy Leigh syn-
drome (Johnson et al., 2013b). Interestingly, rapamycin did not
alter mitochondrial function or electron transport chain complex
I assembly, yet it mitigated a wide range of metabolic derange-
ments and improved overall survival.
Autophagy
Amino acids, macromolecules, and damaged organelles are
degraded and recycled by cells via the multistep process of auto-
phagy.mTORC1 signaling regulates autophagy through inhibitionNeuron 84, October 22, 2014 ª2014 Elsevier Inc. 277
Figure 3. The mTOR Pathway in Neurodevelopmental and Neurodegenerative Diseases
The small inset at the top depicts the physiological regulation of mTOR signaling by a variety of intrinsic and extrinsic factors. Downstream of mTOR, several
cellular processes are regulated, including protein synthesis, mitochondrial biogenesis, and autophagy.
(A) Neurodevelopmental disease: the larger box depicts how loss of NF-1, TSC1/2, or PTEN, or environmental stimuli such as inflammation, epilepsy, or hypoxia
may stimulate mTOR-dependent protein synthesis, resulting in a host of cellular, structural, and physiological responses that culminate in clinical symptoms.
(B) Neurodegenerative disease: the larger box models how changes in these factors may result in dysregulation of mTOR-dependent cellular processes, most
notably autophagy, mitochondrial function, and protein synthesis. Dysfunctional autophagy has been widely associated with neurodegenerative disease.
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mTORC1 with rapamycin stimulates autophagy. In keeping with
its central homeostatic and fundamental role in cellular physi-
ology, autophagy has been linked to a wide spectrum of human
pathology, most notably cancer, metabolic disease, and neuro-
degenerative disorders (Bove´ et al., 2011; Nixon, 2013).
The physiological function of autophagy in the brain remains
unclear; however, genetic disruption of autophagy in the brain
results in tremor, spasticity, axonal degeneration, widespread in-
clusion bodies with ubiquitinated protein, and early death (Hara
et al., 2006; Komatsu et al., 2006, 2007). Significantly, these
phenotypes resemble symptoms associated with neurodegen-
erative diseases characterized by accumulations of misfolded
proteins (Figure 3). Recently, it was shown that autophagy re-
gulates dendritic spine pruning during development, which278 Neuron 84, October 22, 2014 ª2014 Elsevier Inc.may have relevance to mTOR pathway-dependent social behav-
iors (Tang et al., 2014). Importantly, autophagy ismechanistically
distinct in neurons when compared to dividing cells. For ex-
ample, unlike nonneuronal cells, Tsc2-deficient neurons display
increased autolysosome accumulation and retain autophagic
flux despite mTORC1 hyperactivation (Di Nardo et al., 2014).
This is likely the result of a balance between inhibitory effects
of mTORC1 with stimulatory effects of AMPK pathways on the
ULK1 complex. More detailed characterization of the cellular
mechanisms regulating autophagy in neurons will be crucial.
The Functions of mTOR in the Brain
Neural Development and Neural Stem Cells
The mouse mutant ‘‘flat-top’’ carries a mutation in the mTOR
gene and lacks a telencephalon, demonstrating a critical role
Neuron
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Whereas loss of mTOR early in development results in a cata-
strophic exhaustion of early progenitor cells necessary for
brain development, overactivation may rapidly exhaust stem
cell niches resulting in profound pathological consequences. A
recent study expressed amutant of mTOR that permitted activa-
tion of the kinase during specific developmental windows. Early
embryonic activation of mTOR resulted in microcephaly with
preserved hexalaminar cortical architecture whereas activating
mTOR in postmitotic neurons resulted in cortical hypertrophy
and a disruption in cortical lamination, neurodegeneration with
inclusion bodies containing ubiquitinated protein, and early
death (Kassai et al., 2014).
Increased mTOR signaling due to loss of either TSC1/2 or
PTEN results in profound changes in neuronal architecture and
differentiation (Kwon et al., 2006; Tavazoie et al., 2005). TSC1/
2-deficient neurons exhibit defects in cellular maturation as evi-
denced by the aberrant production of multiple axons (Choi et al.,
2008). Loss of TSC1/2 function in hippocampal slice cultures re-
sults in an increased size of both neuronal somata and dendritic
arbors but a decrease in dendritic spine number (Tavazoie et al.,
2005). These findings were corroborated by observation of large
neurons and dysplastic neural/glial cells in mouse models lack-
ing Tsc1 in postmitotic neurons or astrocytes (Meikle et al.,
2007; Uhlmann et al., 2002).
To dissect the role of mTORC1 andmTORC2 in brain develop-
ment, several recent studies have used brain-specific knockout
of the Raptor and Rictor genes, respectively. A brain-specific
Raptor knockout demonstrated microcephaly, a reduction in
cell size, cell death, and early postnatal lethality (Cloe¨tta et al.,
2013). Interestingly, brain-specific Rictor knockouts also
demonstrated a small brain, smaller neuronal somatic size, and
shorter dendritic processes (Thomanetz et al., 2013). The effects
in Rictor knockouts appeared to be independent of mTORC1
activation, as phosphorylation of S6K1 and 4EBP1 did not signif-
icantly differ compared to controls. Despite many similarities in
phenotype, the biochemical relationship between mTORC1
and mTORC2 in the brain remains largely unknown.
Oligodendrocyte-specific knockouts of Raptor or Rictor have
been used to assess the relative contributions of mTORC1 and
mTORC2 to myelination and oligodendrocyte maturation (Ber-
cury et al., 2014; Wahl et al., 2014). Based on these studies,
mTORC1 appears to have a more prominent role than mTORC2
in promoting initiation of myelination, and myelin thickness in the
spinal cord. It is hypothesized that mTORC1 plays a role in the
control of lipogenesis and translation of myelin proteins (Leb-
run-Julien et al., 2014). The most prominent effect on oligoden-
drocyte differentiation was observed in Raptor/Rictor double
knockouts. Thus, although mTOR regulation of myelination is
dominated by mTORC1, there is a synergistic effect of mTORC2
in development of these critical cells.
The interaction of mTOR signaling within and between diverse
cell types in the brain is likely to be critical to the many functions
of the pathway during development. This notion is demonstrated
by comparingmousemodels with a loss of Tsc1 in either neurons
or astrocytes (Meikle et al., 2007; Uhlmann et al., 2002). Both
mousemodels exhibited seizures. Neuronal loss of Tsc1 demon-
strated a significant effect on glial function because micedemonstrate a loss of myelination in the cortex (Meikle et al.,
2007). This finding echoes observations in the mTOR- or Raptor-
ablated spinal cord (Bercury et al., 2014; Lebrun-Julien et al.,
2014; Wahl et al., 2014). Reduction in white matter and impaired
cortical connectivity is an important pathological feature of TSC
(Peters et al., 2013). Regional variances in these changes may
correlate with the incidence of neuropsychiatric phenotypes
such as autism.
mTOR in Circuit Formation
Animal models with disrupted mTOR signaling provide evidence
for a prominent role of the mTOR pathway in formation of func-
tional neural circuits. For example, Tsc2+/mice demonstrated
aberrant retinotopic mapping. This process requires Eph recep-
tor- and ERK-dependent regulation ofmTORC1 (Nie et al., 2010).
This finding, taken together with other reports, demonstrates
that axon guidance in response to extracellular guidance cues
regulates mTOR-dependent pathways, suggesting that regula-
tion of local protein synthesis is a mechanism by which axons
interact with their environment (Yoon et al., 2009). Identification
of the axonal RNAs regulated bymTORwill likely provide insights
into axonal biology and synaptogenesis.
Activity-dependent local translation of protein at or near the
synapse is a critical requirement for formation and maintenance
of synapses (reviewed in Jung et al., 2014). The N-methyl-D-
aspartate antagonist ketamine can increase mTOR pathway
signaling. This increase correlated, at least temporarily, with an
increase in synaptic and activity-dependent proteins such as
Arc and Synapsin, and an increase in dendritic spines in vivo
(Li et al., 2010). Another study demonstrated that in response
to activity, mTOR signaling suppresses the translation of potas-
sium channels in dendrites, potentially affecting neuronal mem-
brane potential (Raab-Graham et al., 2006). These results
suggest that the response to neuronal activity critically engages
mTOR signaling to produce long-lasting changes to neural
circuits.
Aside from neuronal activity and growth factors, other types of
cell-cell interactions also modulate mTOR signaling. One ex-
ample is the recent identification of a role for major histocompat-
ibility class I molecules in regulating insulin-mediated synapse
formation (Dixon-Salazar et al., 2014). These results raise the
possibility of connections between the immune system and
mTOR activity that influence the development of neural circuitry.
Another emerging theme is that during injury to a neuronal
process such as during spinal cord injury or denervation, there
appears to be a recrudescence of developmentally critical pro-
anabolic pathways such as mTOR signaling. In embryonic neu-
rons, mTOR pathway components are enriched in developing
axons and contribute to local protein synthesis (Choi et al.,
2008; Nie et al., 2010). Axonal protein synthesis is also necessary
for growth cone regeneration andmutation of TSC or PTEN stim-
ulates process regeneration after injury (Lu et al., 2014; Park
et al., 2008; Verma et al., 2005).
Synaptic Plasticity, Learning, and Memory
The ability to make changes in synaptic strength is considered
essential to the brain’s ability to store information. A role for
mTOR signaling in synaptic plasticity was first gleaned when ra-
pamycin blocked long-term synaptic facilitation in studies of
Aplysia and crayfish (Beaumont et al., 2001; Casadio et al.,Neuron 84, October 22, 2014 ª2014 Elsevier Inc. 279
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slices with rapamycin strongly impaired protein synthesis-
dependent late phase of long-term potentiation (L-LTP) (Tang
et al., 2002). Tsc1+/ or Tsc2+/mice that exhibit hyperactiva-
tion of mTOR also displayed a reduced threshold for L-LTP
(Ehninger et al., 2008; von der Brelie et al., 2006). Similarly,
knockout of 4E-BP2 (the dominant 4E-BP in the brain) lowered
the threshold for induction of L-LTP by high-frequency stimula-
tion (Banko et al., 2005). On the other hand, genetic ablation
of neither the mTOR inhibitor (and rapamycin target) FKBP12
nor S6K1 completely phenocopied the effect of rapamycin.
FKBP12 knockouts showed enhanced LTP, yet no defect in the
threshold for its development (Hoeffer and Klann, 2010; Hoeffer
et al., 2008). In contrast,S6K1 knockouts demonstrated impaired
early-phase LTP (E-LTP) but normal L-LTP. Thus, mTOR-medi-
ated signaling may have complex roles in modulating synaptic
plasticity through both S6K1 and 4EBP branches of the pathway.
mTORC1 has also been implicated in long-term depression
(LTD), a model of weakened synaptic efficacy in the hippocam-
pus and cerebellum. One form of LTD depends on metabotropic
glutamate receptors (mGluRs). mGluR activation results in
increased ERK-MAPK and PI3K-mTOR signaling and activation
of protein synthesis near synapses. Consistently, inhibition of
protein synthesis or mTOR signaling blocks mGluR-dependent
LTD (Auerbach et al., 2011; Banko et al., 2006; Hou and Klann,
2004; Huber et al., 2000). This is thought to be secondary to local
translation of mRNAs already transported to the dendrite
(Lu¨scher and Huber, 2010). mGluR activity enhances the transla-
tional capacity of dendrites by activation of mTOR and S6K1—
yet mGluR-dependent LTD can still be elicited in S6K1/2 double
knockout mice (Hou and Klann, 2004).
mTORC2 has also emerged as an important regulator of syn-
aptic function. mTORC2 has been linked to control of the actin
cytoskeleton in nonneuronal cells, raising the hypothesis that it
could play a role in regulating neuronal processes (Jacinto
et al., 2004). Disruption of Raptor or Rictor in cultured neurons
impinged on process outgrowth (Urbanska et al., 2012). Fore-
brain-specific disruption of Rictor resulted in defects in the tran-
sition from E-LTP to L-LTP and a decrease in actin cytoskeleton
turnover at hippocampal synapses (Huang et al., 2013). Because
chronic rapamycin treatment reversed behavioral phenotypes of
TSC1/2 mutant mice and can also affect mTORC2, these find-
ings suggest that both mTORC1 and mTORC2 regulate synaptic
physiology and behavior. Indeed, TSC1/2 can stimulate
mTORC2 kinase activity independently of Rheb although this
has not been confirmed in neural tissues (Huang et al., 2008).
In keeping with the abundant neurophysiological evidence
linking mTOR signaling to synaptic plasticity, this pathway has
important roles in cognitive behaviors. For example, Tsc2+/
mice—which show enhanced L-LTP and reduced LTD—demon-
strate defects in hippocampus-dependent learning paradigms,
which are reversible by a short course of rapamycin administra-
tion even in adulthood (Ehninger et al., 2008). S6K1 knockouts
demonstrate abnormal fear conditioning and defective hippo-
campus-based learning while 4EBP2 knockouts demonstrate
marked defects in spatial learning (Antion et al., 2008; Banko
et al., 2007). Because S6K1 and 4EBP2 loss are expected to
have at least partially opposing net downstream effects, these280 Neuron 84, October 22, 2014 ª2014 Elsevier Inc.data suggest that any disruption in mTOR downstream signaling
can affect cognition. These experiments highlight an emerging
theme that an exquisite balance of mTOR signaling regulates
synaptic function and behavior. Supporting this notion, Tsc1
forebrain-specific mutants demonstrate hyperexcitability and a
disruption in excitatory/inhibitory (E/I) balance in hippocampal
networks (Bateup et al., 2013).
Homeostatic Regulation
The maintenance of energy balance is a fundamental require-
ment of all living things, requiring the constant scaling of nutrient
intake, metabolic demand, and motivational state. In mammals,
the control of feeding is primarily integrated by opposing neuro-
transmitter and neuropeptide cell populations in the arcuate nu-
cleus of the hypothalamus (Sternson, 2013; Woods et al., 2008).
mTOR signaling appears to have a prominent, albeit complex,
role in the molecular control of feeding behavior. Phosphoryla-
tion of S6K1 in the hypothalamus decreased with starvation,
whereas overactivation of mTOR in catabolic pro-opiomelano-
cortin neurons reduced their activity and resulted in disinhibition
of feeding and obesity (Cota et al., 2006; Mori et al., 2009; Yang
et al., 2012). Treatment with the satiety signal leptin stimulated
the phosphorylation of S6K1 and S6 in the hypothalamus in a ra-
pamycin-dependent fashion suppressing feeding. Thus, leptin
signals satiety and conveys the signal to activate growth and
anabolism. Consistently, rapamycin administration stimulated
feeding but completely blocked the anorectic effects of leptin,
consistent with the hypothesis that leptin signaling is mTOR
dependent (Cota et al., 2006). In aged mice, chronic rapamycin
administration inhibited feeding, consistent with the pro-
longevity effects of mTOR pathway suppression through mech-
anisms analogous to caloric restriction (Harrison et al., 2009;
Johnson et al., 2013a; Kapahi and Zid, 2004). The neural mech-
anisms underlying this apparent discrepancy in age-dependent
mTOR-related signaling in the hypothalamus remain unclear.
Circadian rhythms are 24-hr oscillations in behavior, gene
expression, and physiology regulated by an autonomous tran-
scriptional-translational-posttranslational feedback loop (Taka-
hashi et al., 2008). Although light has been shown to activate
phospho-S6 and phospho-S6K1 in the suprachiasmatic nucleus
of the hypothalamus (SCN), the mechanisms by which activation
of the mTOR pathway impacts circadian timing remain obscure
(Cao et al., 2010). A recent study points to 4EBP-dependent
translational regulation of vasoactive intestinal peptide in the
SCN as a mechanism that regulates phase shifts in response
to light (Cao et al., 2013).
The circadian timekeeping system forms the foundation for
rhythmic behaviors, including sleep-wake oscillations (Saper
et al., 2005). Genetic and microarray studies of sleep deprivation
in mammals and flies have implicated the regulation of synaptic
protein homeostasis as one of the major effects of sleep (Tononi
and Cirelli, 2007). Interestingly, sleep mediates developmental
cortical plasticity in an mTOR-dependent fashion (Seibt et al.,
2012; Seibt and Frank, 2012).
Neuropathology of mTOR
Monogenic Disorders of the mTOR Pathway
Tuberous Sclerosis Complex. Tuberous sclerosis complex (TSC)
is an autosomal dominant multisystem disorder caused by loss
Table 1. Neurological Disorders Associated with Dysfunctional mTOR Pathway Signaling
Disease Responsible Gene Product Neurological Manifestations
Pathway
Activity Reference
Neurodevelopmental
Tuberous sclerosis complex TSC1 or TSC2 E, ASD, ID, tubers, hamartomas,
multisystem benign tumors
up Crino et al., 2006
TBC1D7 syndrome? TBC1D7 ID, macrocrania, neuropsychiatric up? Alfaiz et al., 2014
Autism spectrum with
macrocephaly
PTEN ASD, E, MacroC up Zhou and Parada, 2012
Cowden syndrome PTEN MacroC, ± ID, CA up Pilarski et al., 2013
Bannayan-Riley-Rulvalcaba
syndrome
PTEN MacroC, polyps, ± ID, skin,
WM cysts
up Pilarski et al., 2013
Lhermitte-Duclos disease PTEN dysplastic gangliocytomas of
the cerebellum
up Pilarski et al., 2013
Neurofibromatosis type I NF1 ID, E, OPG up Diggs-Andrews and
Gutmann, 2013
Nonsyndromic autism PTEN, mTOR, ?AKT, others. ASD, E? up/down O’Roak et al., 2012
Epileptic encephalopathy mTOR, others E, ID ? Allen et al., 2013
Neurodegenerative
Alzheimer disease APP, Presenilins, others dementia up? Caccamo et al., 2011;
Spilman et al., 2010
Parkinson disease a-synuclein, Parkin, PINK1,
LRRK2, others
movement disorder, dementia up? Bove´ et al., 2011
Huntington disease Huntingtin movement disorder,
neuropsychiatric
up? Ravikumar et al., 2004
Psychiatric
Major depressive disorder ? decreased mood, suicidality down? Autry et al., 2011;
Li et al., 2011
Schizophrenia AKT1, DISC1, others hallucinations, delusions,
thought disorder, depression
up/down? Emamian et al., 2004;
Kim et al., 2009;
Zhou et al., 2013
ASD, autism spectrum disorder; E, epilepsy; ID, intellectual disability; MacroC, macrocephaly; MicroC, microcephaly; OPG, optic pathway glioma;
WM, white matter.
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monogenetic ‘‘mTORopathies.’’ TSC affects 1/6,000 individuals
worldwide (Crino et al., 2006). TSC manifests as a tumor-hamar-
toma syndrome affecting multiple organs including the brain,
skin eyes, kidneys, heart, and lungs. TSC results in epilepsy
(approximately 90% of patients), intellectual disability (approxi-
mately 50%), autism (approximately 50%), and other neuro-psy-
chiatric morbidities including sleep disruption, attention-deficit
hyperactivity disorder, and anxiety (Asato and Hardan, 2004;
Bruni et al., 1995; Hunt and Stores, 1994; Husain et al., 2000)
(Table 1). Missense mutations have been identified in over 700
locations for TSC2 and more than 200 in TSC1 without clear ev-
idence for particular areas of vulnerability within either gene
product (Dabora et al., 2001; Sancak et al., 2005). As a result,
genotype-phenotype characterization has been difficult (van
Slegtenhorst et al., 1999). TSC2 mutations seem to render a
more severe phenotype, in keeping with its role as a functional
GAP in the TS complex (Dabora et al., 2001) (Figure 3).
The pathognomonic lesion in TSC brain is the cortical tuber
and is present in over 80% of patients. Tubers are poorly under-
stood, nonmalignant, abnormalities of the developing cerebral
cortex characterized histologically as a loss of normal corticallamination, dysplastic neurons cells, large glial cells, and ‘‘giant
cells.’’ Cortical tuber burden was thought to correlate with the
severity of neurologic symptoms. However, even patients
without tubers can have very significant neurological symptoms
including autism and intellectual disability. Still, seizure foci often
localize to regions surrounding tubers, suggesting that they are
indeed epileptogenic (Mohamed et al., 2012).
Tumors in TSC are thought to arise from a loss of heterozygos-
ity (LOH) resulting in an mTOR-hyperactivated state in homozy-
gous null cells. LOH has been convincingly demonstrated in
most of the neoplasms associated with TSC including subepen-
dymal giant cell astrocytomas (SEGAs), angiomyolipomas, car-
diac rhabdomyomas, and lymphangioleiomyomatosis (LAM).
Biallelic inactivation has been detected, but in only a small num-
ber of cells within cortical tubers (Crino et al., 2010; Qin et al.,
2010).
With regard to risk of neuropsychiatric symptoms, tuber vol-
ume may be a better marker than total tuber number (Jansen
et al., 2008). With increasingly sophisticated modes of neuroi-
maging, more subtle and complex abnormalities in the TSC brain
have been identified, including changes in white matter volume,
myelination, and connectivity (Peters et al., 2013). TheseNeuron 84, October 22, 2014 ª2014 Elsevier Inc. 281
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For example, impaired connectivity of the arcuate fasciculus—
the tract that connects Broca’s and Wernicke’s areas—is more
common in patients with TSC that have autism compared to
TSC patients without autism (Lewis et al., 2013). The cortex is
not the only site of important CNS pathology in TSC. Emerging
evidence has suggested that TSC patients have lesions in other
brain areas including the cerebellum (Boer et al., 2008; Ertan
et al., 2010; Reith et al., 2011).
Whereas the TSC1/TSC2 complex interacts with more than 50
proteins, most remain poorly understood. One exception is the
recently described TBC1D7, a TSC1-dependent component of
the TSC1/2 complex that functions similarly to TSC1 and TSC2
on a cellular level (Dibble et al., 2012; Menon et al., 2014). Two
recent studies have described humans carrying mutations in
TBC1D7, which manifested clinically with intellectual disability,
macrocrania (large skull), and anxiety. Because none of the
cases had epilepsy, autism, tubers, or SENs, TBC1D7mutations
seem to diverge phenotypically from TSC1/2 mutations, at least
in brain (Alfaiz et al., 2014; Capo-Chichi et al., 2013).
PTEN Hamartoma Tumor Syndrome. PTEN is a dual specificity
phosphatase that inhibits both the PI3K/AKT and MAPK path-
ways, and thus curbs mTOR signaling (reviewed in Zhou and
Parada, 2012). PTEN is well understood to be an important hu-
man tumor-suppressor gene and its activity is a major regulator
of growth mediated by the AKT/mTOR pathway. Germline muta-
tions in PTEN are responsible for a group of rare disorders
referred to as PTENhamartoma tumor syndromes (PHTS) (Ender-
sby and Baker, 2008; Pilarski et al., 2013). These include Cowden
syndrome (CS), Lhermitte-Duclos disease (LDD), and Bannayan-
Riley-Ruvacalba syndrome (BRRS). CS is characterized by
macrocephaly and benign hamartomas of the breast, thyroid, or
endometrium, as well as malignant tumors. A minority of patients
have comorbid intellectual disability. LDD is characterized by
dysplastic gangliocytomas of the cerebellum, which clinically
cause ataxia, seizure, or increased intracranial pressure (Ender-
sby and Baker, 2008). BRRS is the association of macrocephaly,
developmental delay, neurocutaneous features, and/or intestinal
polyps (Lynch et al., 2009). Mysteriously, the same mutations in
PTEN can result in CS, LDD, orRBBS, suggesting thatmany other
factors cooperate to render specific phenotypes (Pilarski et al.,
2013; Rodrı´guez-Escudero et al., 2011). In general, as in TSC,
there is a poor genotype-phenotype correlation in PHTS (Table 1).
Interestingly,PTENmutations that spare the lipid phosphatase
domain are emerging as relatively common sporadic causes of
autism, especially when associated with comorbid macroce-
phaly (which is associated with autism in approximately 10%–
20% of cases) (Butler et al., 2005; Hobert et al., 2014; Klein
et al., 2013; Varga et al., 2009; Zhou and Parada, 2012). As
mentioned above, PTEN mutations have been estimated to
occur in about 1% of sporadic autism, and PTEN gene testing
is frequently recommended when macrocephaly is present
with clinical features of autism (O’Roak et al., 2012). With striking
similarity to human disease, mouse models with deletion of Pten
in forebrain neurons results in macrocephaly, seizures, and
abnormal social interaction (Kwon et al., 2006). Pathologically,
neurons demonstrate enlarged somata, increased length of
both dendritic arbors and number of dendritic spines. Thus,282 Neuron 84, October 22, 2014 ª2014 Elsevier Inc.the phenotype is similar but nonidentical to that of TSC, possibly
reflecting the many subtleties in the signaling pathway that await
future discovery.
Neurofibromatosis. Neurofibromatosis (NF1) is a common
neurocutaneous disorder characterized by both benign and ma-
lignant tumors of the central and peripheral nervous system. NF1
is autosomally inherited in 1/2,500-1/3,000 live births. It has
diverse manifestations in tissues that are primarily, although
not exclusively, of neural crest origin. Clinical features of NF1
include the brain (glial tumors, macrocephaly), skin (cafe´ au lait
spots, freckling, neurofibromas), bone (sphenoid wing dys-
plasia), kidney (renal artery stenosis), and endocrine systems.
Although epilepsy is seen in a relatively small percentage of
cases (<10%), learning disabilities, attention-deficit hyperactivity
disorder, sleep disruption, and anxiety are very common. Optic
pathway gliomas occur in 15% of patients. Plexiform neurofi-
bromas can undergo malignant transformation, and 3%–5% of
patients with NF1 develop malignant peripheral nerve sheath
tumors. As in PTHS, macrocephaly is common (Table 1).
Mutations in the neurofibromin 1 (NF1) gene result in this dis-
ease.NF1 encodes a GTPase-activating protein that suppresses
the activity of the proto-oncogene Ras. In mice with a targeted
disruption of the Nf1 gene, Schwann cells have increased levels
of Ras activation and an increased growth rate. In its active state,
Ras signals to several downstream effectors, including the ERK/
MEPK and the PI3K/mTOR signaling pathways (Dasgupta and
Gutmann, 2005; Dasgupta et al., 2005; Johannessen et al.,
2005). Whereas mTORC1 activity is essential for tumorigenesis
downstream of NF1 loss (Johannessen et al., 2008), NF1-medi-
ated regulation of mTORC1 appears independent of TSC/Rheb
(Banerjee et al., 2011). Clinical trials are in progress to test the
efficacy of mTOR inhibitors and dual PI3K/mTOR inhibitors in
NF1-related tumors (Endo et al., 2013).
Neurofibromin also plays a role in neurons. Nf1+/ mice also
have learning andmemory deficits. Lovastatin, which is an inhib-
itor of the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMG-
CoA-reductase), and thus a blocker of Ras signaling, reversed
spatial learning deficit and impairment of attention (Costa
et al., 2001). Whether mTOR plays any role in neurons down-
stream of NF1 loss is unclear.
Other Neurodevelopmental Disorders
Fragile X Syndrome. The fragile X mental retardation protein 1
(FMRP) is deficient in a commonly inherited form of intellectual
disability, fragile X syndrome (FXS). FMRP1 is an important
translational repressor of hundreds of mRNAs in the brain (Dar-
nell et al., 2011). In Fmr1/y mutant mice, mTOR signaling is
high, protein synthesis is elevated, and mGluR-dependent LTD
is exaggerated (Auerbach et al., 2011; Huber et al., 2002;
Sharma et al., 2010). Genetic deletion of S6K1 in Fmr1/y
mice reduced exaggerated protein synthesis and mitigated
neurophysiological and behavioral defects (Bhattacharya et al.,
2012). In addition, lovastatin rescued many of the phenotypes
of Fmr1 mutants (Osterweil et al., 2013). While investigating the
relationships between Tsc2+/ and Fmr1/y mouse pheno-
types, Bear and colleagues made the surprising finding that
Tsc2+/ mice had reduced protein synthesis in the hippocam-
pus. Fmr1/y;Tsc2+/ double mutants demonstrated normali-
zation in hippocampal mGluR-LTD, protein synthesis rates,
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ance one another (Auerbach et al., 2011). Whether this interac-
tion occurs in other regions of the brain is not clear, and the
biochemical events that might mediate such a relationship
have not yet been determined.
Autism. Autism is a neurodevelopmental disorder defined by
two cardinal features: (1) persistent social communication and
social interaction deficit, and (2) restricted and repetitive patterns
of behavior. Whereas the causes of autism appear heteroge-
neous, several genetic disorders that directly affect mTOR
signaling are associated with autism, nominating this pathway
as a possible etiological hub for the disorder. TSC patients
display an autistic profile very similar to that of idiopathic autism
(Jeste et al., 2008). Mutations in the PTEN gene have been esti-
mated to cause 1%–5% of cases of autism (Zhou and Parada,
2012). The high frequency of autism in monogenetic mTORopa-
thies has suggested that regulation of mRNA translation may be
a critical variable in the development of autism.
Studies in animal models have corroborated findings from hu-
man genetics. Tsc1+/ and Tsc2+/ mice and the spontane-
ously haploinsufficient Tsc2+/ Eker rat demonstrate abnormal
social interaction reversible by rapamycin treatment (Ehninger
et al., 2008; Goorden et al., 2007; Sato et al., 2012; Waltereit
et al., 2011). Forebrain-specific deletion of Pten also resulted in
abnormal social behavior (Kwon et al., 2006). Deletion of Tsc1
or Tsc2 in cerebellar Purkinje cells resulted in marked abnormal-
ities in social behavior, directly implicating mTOR signaling in the
cerebellum as a mediator of social cognition (Reith et al., 2013;
Tsai et al., 2012). 4E-BP2 knockout mice demonstrated
autism-like features, thereby directly implicating mTOR-depen-
dent protein synthesis in the control of social behavior (Gkogkas
et al., 2013). Moreover, these mice demonstrated increased
translation of the neuroligins, proteins that have been previously
linked to ASD risk (Su¨dhof, 2008). Remarkably, suppression of
neuroligin 1 partially reversed the behavioral phenotypes in these
mice (Gkogkas et al., 2013). In a parallel study, overexpression of
eIF4E similarly resulted in defective social behavior and hippo-
campal physiology (Santini et al., 2013). These studies have illu-
minated translational regulation pathways as crucial mediators
of higher order cognitive function and suggest that manipulation
of these pathways may be pharmacological targets for treating
autism.
Epilepsy. Epilepsy is a common neurological disorder af-
fecting approximately 1% of population worldwide. Seizures
are paroxysmal electrical events in the brain, often resulting in
behavioral manifestations. The mainstay of therapy is anticon-
vulsant medications that address the symptoms but not the
cause of the disorder. ThemTORpathway has received attention
as a potential mediator of epilepsy since the connection between
TSC and mTOR was made about a decade ago. It was initially
recognized that mTOR is hyperactive in cells from cortical tubers
and focal cortical dysplasias (Baybis et al., 2004; Miyata et al.,
2004). More recently, several groups identified de novo somatic
mutations of PI3K, AKT3, or mTOR genes in hemimegalence-
phaly, a condition associated with severe seizures (Lee et al.,
2012; Poduri et al., 2012; Rivie`re et al., 2012). Human mutations
in DEPDC5, a component of the GATOR complex, have been
linked to both epilepsy with cerebral malformations and nonle-sional epilepsy (Bar-Peled et al., 2013; Dibbens et al., 2013;
Scheffer et al., 2014).
Animal models have further supported this association be-
tween mTOR and epilepsy. Essentially all neural mutant models
of Tsc1 or Tsc2 homozygous loss lead to increased seizures
(Carson et al., 2013; Goto et al., 2011; Meikle et al., 2007; Nor-
mand et al., 2013; Uhlmann et al., 2002; Zeng et al., 2011). Simi-
larly, Pten knockout also leads to epilepsy in mice (Pun et al.,
2012; Zhou et al., 2009). Importantly, epilepsy due to loss of
Tsc1, Tsc2, or Pten all respond to rapamycin treatment, indi-
cating the mTOR hyperactivation is necessary for this pheno-
type. Rapamycin seems effective in not only reducing seizures
once they start, but also in preventing seizures from ever devel-
oping indicating that mTORmay have an antiepileptogenic effect
in these genetic models (Meikle et al., 2008; Zeng et al., 2008).
This has led to preclinical trials with mTOR inhibitors in other
models of epileptogenesis, such as posttraumatic epilepsy (Ber-
dichevsky et al., 2013; Guo et al., 2013; Huang et al., 2010).
There are also some reports of mTOR inhibitors in temporal
lobe epilepsy models, but the level of efficacy seems to differ
(Buckmaster and Lew, 2011; Zeng et al., 2009).
A recent genomics study of infantile spasms and Lennox-Gas-
taut syndrome—forms of epileptic encephalopathy—identified a
patient with de novo mutation in the mTOR gene itself, without
accompanying brain malformations. The result establishes
mTOR as a cause for these disorders and suggests that mTOR
inhibitors represent possible treatments (Allen et al., 2013).
How mTOR mediates epileptogenesis is not yet clear. Given
the many cellular and developmental functions of mTOR in
neuronal differentiation, migration, axonal growth/sprouting,
and dendrite morphogenesis, it is likely that mTOR hyperactiva-
tion contributes to aberrant circuit formation. However, it is also
likely that mTOR regulates neuronal excitability in already estab-
lished neural circuits. Consistent with this model, Tsc1 inacti-
vation in adult mice is rapidly followed by mTOR-dependent
seizures (Abs et al., 2013).
One important concept to emphasize is thatmTORactivity can
be regulated by several nongenetic factors such as neuronal
activation, hypoxia, and inflammatory responses. Thus, a combi-
nation of genetic ‘‘hits’’ (such as TSC1/2 or PTEN loss) and
nongenetic ‘‘hits’’ (such as epilepsy, inflammatory response,
etc.) could synergistically hyperactivate mTOR and contribute
to a common pathology (Figure 3B). Such combinatorial effects
are just beginning to be explored and may provide one explana-
tion for the variability of expression for genetic mTORopathies
and may provide options for treatment as well (Ehninger et al.,
2012; Waltereit et al., 2011).
Neurodegenerative Disease
Aging. One of the most compelling influences on extending life-
span across phyla is caloric intake. As a major gauge of nutrient
signaling and energy balance, the mTOR pathway has emerged
as a crucial hub in the regulation of overall lifespan (reviewed in
Johnson et al., 2013a). There is an increasing body of pharmaco-
logic and genetic data to support a role for mTOR in organismal
longevity, particularly in females. Rapamycin extends the life-
span of various mouse strains; for reasons that remain unclear,
the effect was greater in female mice (Harrison et al., 2009). Simi-
larly, S6K1 knockout females demonstrated an extension ofNeuron 84, October 22, 2014 ª2014 Elsevier Inc. 283
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span extension in response to dietary restriction, suggesting that
protein synthesis is essential to the effects of caloric restriction
on aging (Zid et al., 2009). How mTOR might mediate longevity
in animals, whether mitochondrial function or autophagy are
involved in this effect, and the role of female hormones such as
estrogen that signal through mTOR are modifying these func-
tions remain unanswered.
Alzheimer’s Disease. Alzheimer’s disease (AD) is character-
ized clinically by progressive loss of short-term memory and
cognitive dysfunction. The pathological hallmarks of this disor-
der are the accumulation of extracellular senile plaques and
intracellular neurofibrillary tangles (NFT). The amyloid cascade
hypothesis posits that abnormalities in the sequential cleavage
of the amyloid precursor protein (APP) by b-secretase and then
g-secretase results in the generation of toxic oligomeric Ab spe-
cies, which initiate a cascade of cellular dysfunction resulting in
synaptic and ultimately neuronal loss (reviewed in Pei and
Hugon, 2008; Wang et al., 2014).
Ab accumulation correlates with an increase in mTOR
signaling with increased levels of phosphorylated S6K1 accom-
panying the appearance of NFTs in postmortem AD brain tissue
(An et al., 2003). Accumulation of autophosphorylated mTOR at
S2481 correlated with presence of pathological forms of tau and
phospho-tau proteins (Li et al., 2005). Increased levels of AKT
and its substrates were also identified in the temporal cortex of
AD brains (Griffin et al., 2005). Pharmacologic or genetic manip-
ulations that decrease the amount of Ab in mouse brain are asso-
ciated with corresponding decreases in mTOR pathway activity
(Caccamo et al., 2011). Inhibition of mTOR signaling has a bene-
ficial effect on both pathophysiological and behavioral outcomes
in several mouse models of Ab pathology (Caccamo et al., 2011;
Spilman et al., 2010; Zhang et al., 2010). Because of the impor-
tant role of autophagy in the clearance of misfolded protein ag-
gregates, autophagy dysfunction has been implicated in AD
pathogenesis, and the stimulation of autophagy by mTOR inhibi-
tion is being tested as a potential therapeutic agent (Nixon,
2013).
Parkinson’s Disease. Parkinson’s disease (PD) is a common
and debilitating neurodegenerative disorder characterized by
resting tremor, bradykinesia, postural and autonomic instability,
and rigidity. The pathological signature of PD is the loss of dopa-
minergic neurons in substantia nigra and the accumulation of
a-synuclein-containing inclusion bodies (i.e., Lewy bodies).
Increased numbers of autophagosomes have been reported in
postmortem PD brains (Anglade et al., 1997). The accumulation
of toxic proteins in PD brains suggests that in some cases, de-
fects in autophagy may promote pathogenesis. An extension
of this hypothesis is that the stimulation of autophagy could
induce the appropriate handling of protein accumulations. Rapa-
mycin induced autophagy and blocked the accumulation of
ubiquitinated a-synuclein in a-synuclein-overexpressing cells
and mice (Spencer et al., 2009; Webb et al., 2003). On the other
hand, overexpression of constitutively activated AKT was also
protective to both neuronal cell bodies and axons of the nigros-
triatal projections in PD mouse models (Cheng et al., 2011; Ries
et al., 2006). Thus, the mTOR pathway appears to participate in
several ways in PD pathogenesis.284 Neuron 84, October 22, 2014 ª2014 Elsevier Inc.Huntington’s Disease. Huntington’s disease (HD) is an auto-
somal dominant genetic disorder characterized by progressive
motor disorder, psychiatric dysfunction, and eventually, demen-
tia. Disease-causing mutations in the huntingtin (HTT) gene
result in expansion of polyglutamine repeats (CAG) in HTT and
are thought to lead to the formation of pathogenic protein aggre-
gates (reviewed in Nixon, 2013; Ross et al., 2014). When more
than 35 repeats occur, disease ensues. It was hypothesized
over a decade ago that stimulation of the clearance of HTT ag-
gregates by stimulation of autophagy would benefit disease pro-
gression. Mutant HTT stimulates mTOR pathway activation
and TOP-dependent translation in heterologous cell lines in cells
expressing 74 CAG repeats (Q74) protein compared to those ex-
pressing the shorter, Q23 form, suggesting that the suppression
of autophagy may promote HD pathogenesis (Ravikumar et al.,
2004). It remains unclear whether the activation of mTOR is
essential to, or a compensation for, HD pathogenesis. In some
studies, inhibition of mTOR-independent autophagy is protec-
tive (Tsvetkov et al., 2010). Others have shown that targeting
the catalytic domain of mTOR is more effective than rapamycin
analogs (Roscic et al., 2011).
Psychiatric Disease
Major depressive disorder is a debilitating, common, and costly
worldwide illness. The N-methyl-D-aspartate receptor antago-
nist ketamine has been used with success for treatment-resis-
tant depression (Berman et al., 2000; Zarate et al., 2006). Several
reports over the past few years have directly implicated the
mTOR pathway in mediating the rapid antidepressant effects
of ketamine. Notably, ketamine administration to rats resulted
in a rapid increase in phosphorylated mTOR, S6K1, and 4EBP.
These biochemical changes correlated with increases in synap-
tic protein expression and synapse number at dendritic spines in
the prefrontal cortex. Moreover, ketamine’s ability to ameliorate
depressive symptoms was completely abrogated by preadmi-
nistration with rapamycin, suggesting that the effect of ketamine
is mTOR dependent (Li et al., 2010, 2011). Ketamine has also
been shown to disinhibit BDNF translation in a manner depen-
dent on the S6K1 substrate eEF2K (Autry et al., 2011). An unre-
solved question is to what extent clinical depression results from
acute or chronic dysfunction in mTOR signaling.
Schizophrenia is a common, chronic, and severe neuropsy-
chiatric disorder characterized by delusions, hallucinations,
disorganized thought and behavior, and affective flattening.
Schizophrenia is estimated to affect 1% of the general popu-
lation. A clear role for mTOR signaling in schizophrenia patho-
genesis has not been established; however, inhibition of the
disrupted in schizophrenia 1 (DISC1) gene product, a possible
susceptibility locus for bipolar disorder and schizophrenia, re-
sulted in increased phospho-AKT and phospho-S6 expression,
neuronal hypertrophy, abnormal dendritic morphology, and hy-
perexcitability accompanied by learning and memory deficits
and depressive behavior (Kim et al., 2009; Zhou et al., 2013). Ra-
pamycin was able to reverse the biochemical and behavioral ef-
fects of DISC1 knockdown, consistent with the hypothesis that
one endogenous function of DISC1 is to curb mTOR signaling
(Kim et al., 2009).
Studies from humans have shown a decrease in AKT1
signaling in the brain and peripheral lymphocytes of individuals
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brain-specific Rictor knockout showed a reduction in dopamine
in the prefrontal cortex, elevated expression of norepinephrine
transporter, and deficits in prepulse inhibition, a schizophrenia-
associated endophenotype (Siuta et al., 2010). Thus, an increase
in mTORC1 signaling secondary to suppression of DISC1 or a
decrease in mTORC2 signaling secondary to loss of Rictor or
AKT1 signaling may contribute to schizophrenia-like phenotypes
in rodents.
Therapeutics
Since the discovery of rapamycin in the 1960s, mTOR inhibi-
tors have been used to prevent solid organ transplant rejection,
to augment anticancer treatment regimens, and to prevent
neovascularization of artificial cardiac stents. Once the rela-
tionship between TSC genes and the mTORC1 pathways
was established, case series of TSC patients treated with rapa-
mycin were reported (Franz et al., 2006). Subsequent clinical
trials led to the approval of everolimus for SEGAs in TSC by
the US Food and Drug Administration in 2010 and the Euro-
pean Medicines Agency in 2011, becoming the first ever
approved therapy for patients with TSC (Krueger et al., 2010).
Everolimus is approved by the US Food and Drug Administra-
tion for treatment of SEGAs at any age and for renal angiomyo-
lipomas over the age of 18. Subgroup analysis of everolimus-
treated patients in the SEGA trial revealed improved fractional
anisotrophy measures as a marker for white matter integrity on
magnetic resonance diffusion tensor imaging, consistent with
effects seen in mouse models (Meikle et al., 2008; Tillema
et al., 2012). These findings suggest that white matter integrity
on diffusion tensor imaging may be a biomarker of TSC-asso-
ciated neurocognitive deficits and respond to mTOR inhibitors
(Peters et al., 2013). Recently, the first prospective phase I/II
trial of 20 patients with TSC showed that 12 weeks of everoli-
mus treatment resulted in a reduction of seizure frequency and
duration, increased quality of life, and improved behaviors, as
reported by parents (Krueger et al., 2013). Rapamycin has
been reported to have efficacy to treat other manifestations
of TSC associated with kidneys, lungs, and skin (Bissler
et al., 2008; Davies et al., 2011; Haemel et al., 2010; McCor-
mack et al., 2011). Additional multicenter randomized, pla-
cebo-controlled, double-blind phase II and phase III clinical
trials are also underway to test the efficacy of everolimus sepa-
rately for neurocognition and epilepsy (NCT01289912 and
NCT01713946).
Although rapalogs (allosteric inhibitors of mTOR) have been
quite successful in clinical trials of TSC, their penetrance of
blood-brain barrier is relatively poor. Furthermore, they preferen-
tially inhibit mTORC1 rather than mTORC2 and have differential
effects on S6K and 4E-BP1 arms of the downstream signaling
pathways (Liu et al., 2006). Direct nonallosteric mTOR kinase in-
hibitors are currently in clinical development and display much
stronger and complete suppression of mTORC1 kinase activity.
Whether such compounds will enter the CNS and be effective
and safe in diseases such as TSC is not yet known. Whether
the combination of mTORC1 inhibitors with extracellular factors
(ephrins, diet, etc.) may have synergistic effects has not been yet
explored.Conclusions and Future Prospects
It is becoming clear that mTOR represents a point of conver-
gence in brain disorders. While much attention has focused on
the role of mRNA translation at the synapse, the identity of
neuronal mRNAs regulated by the mTOR pathway still needs
to been elucidated. Furthermore, mTOR regulates not only pro-
tein synthesis, but also a plethora of metabolic processes and
cytoskeletal dynamics, which are not well studied in neurons.
The availability of rapalogues that can be used in proof-of-
concept trials has accelerated research in this field. A deeper
understanding of the fundamental roles of mTOR in neurodevel-
opment and degeneration may have implications not only for the
prototypical mTORophathies such as TSC, but also for a whole
host of neurological disorders for which we desperately need
therapies.
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